Teva Pharmaceutical Industries (TEVA) Gross Margin (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Gross Margin across 11 years of filings, most recently posting 49.52% for Q1 2026.

• Quarterly Gross Margin rose 128.0% year-over-year to 49.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 52.07% (down 137.0% YoY) and the FY2025 annual result came in at 51.79%, up 305.0% from the prior year.
• Gross Margin slipped to 49.52% in Q1 2026, from 56.38% in the prior quarter.
• Over five years, Gross Margin peaked at 73.14% in Q4 2024 and troughed at 43.21% in Q1 2023.
• A 5-year average of 50.14% and a median of 48.24% in 2025 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2024 — Gross Margin jumped 1893 bps — and 2025, when it sank 1676 bps.
• Tracing TEVA's Gross Margin over 5 years: stood at 45.57% in 2022, then grew by 19 bps to 54.21% in 2023, then surged by 35 bps to 73.14% in 2024, then fell by 23 bps to 56.38% in 2025, then dropped by 12 bps to 49.52% in 2026.
• Business Quant data shows TEVA's Gross Margin at 49.52% in Q1 2026, 56.38% in Q4 2025, and 51.43% in Q3 2025.